Evidence map›Paper›PMID 35323507›Full record

ReviewMarine drugs2022

Exploring Marine as a Rich Source of Bioactive Peptides: Challenges and Opportunities from Marine Pharmacology.

Ishtiaq Ahmed, Muhammad Asgher, Farooq Sher, Syed Makhdoom Hussain, Nadia Nazish, Navneet Joshi, Ashutosh Sharma, Roberto Parra-Saldívar, Muhammad Bilal, Hafiz M N Iqbal

Open access · goldAbstract readReview
In one paragraph

Review in Marine drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Step Enzymatic Hydrolysis andFoods (Basel, Switzerland) · 2025
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 6 countries.

Ishtiaq AhmedMenzies Health Institute Queensland, School of Medical Science, Griffith University, Gold Coast Campus, Gold Coast, QLD 4222, Australia.ORCID 0000-0003-3682-0812
Muhammad AsgherDepartment of Biochemistry, University of Agriculture Faisalabad, Faisalabad 38000, Punjab, Pakistan.
Farooq SherDepartment of Engineering, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, UK.ORCID 0000-0003-2890-5912
Syed Makhdoom HussainFish Nutrition Lab, Department of Zoology, Government College University Faisalabad, Faisalabad 38000, Punjab, Pakistan.
Nadia NazishDepartment of Zoology, University of Sialkot, Sialkot 51040, Punjab, Pakistan.
Navneet JoshiDepartment of Biosciences, School of Liberal Arts and Sciences, Mody University of Science and Technology, Lakshmangarh, Sikar 332311, India.ORCID 0000-0003-0155-3785
Ashutosh SharmaTecnologico de Monterrey, School of Engineering and Sciences, Centre of Bioengineering, Av. Epigmenio González No. 500, Fracc. San Pablo, Queretaro 76130, Mexico.ORCID 0000-0002-9000-1378
Roberto Parra-SaldívarTecnologico de Monterrey, School of Engineering and Sciences, Monterrey 64849, Mexico.ORCID 0000-0002-4958-5797
Muhammad BilalSchool of Life Science and Food Engineering, Huaiyin Institute of Technology, Huai'an 223003, China.ORCID 0000-0001-5388-3183
Hafiz M N IqbalTecnologico de Monterrey, School of Engineering and Sciences, Monterrey 64849, Mexico.ORCID 0000-0003-4855-2720
Tecnológico de Monterrey · MXGovernment College University, Faisalabad · PKGriffith University · AUHuaiyin Institute of Technology · CNMody University of Science and Technology · INNottingham Trent University · GBUniversity of Faisalabad · PKUniversity of Sialkot

Funding

Consejo Nacional de Ciencia y Tecnología CVU: 735340
6 · The paper itself

Abstract

This review highlights the underexplored potential and promises of marine bioactive peptides (MBPs) with unique structural, physicochemical, and biological activities to fight against the current and future human pathologies. A particular focus is given to the marine environment as a significant source to obtain or extract high-value MBPs from touched/untouched sources. For instance, marine microorganisms, including microalgae, bacteria, fungi, and marine polysaccharides, are considered prolific sources of amino acids at large, and peptides/polypeptides in particular, with fundamental structural sequence and functional entities of a carboxyl group, amine, hydrogen, and a variety of R groups. Thus, MBPs with tunable features, both structural and functional entities, along with bioactive traits of clinical and therapeutic value, are of ultimate interest to reinforce biomedical settings in the 21st century. On the other front, as the largest biome globally, the marine biome is the so-called "epitome of untouched or underexploited natural resources" and a considerable source with significant potentialities. Therefore, considering their biological and biomedical importance, researchers around the globe are redirecting and/or regaining their interests in valorizing the marine biome-based MBPs. This review focuses on the widespread bioactivities of MBPs, FDA-approved MBPs in the market, sustainable development goals (SDGs), and legislation to valorize marine biome to underlying the impact role of bioactive elements with the related pathways. Finally, a detailed overview of current challenges, conclusions, and future perspectives is also given to satisfy the stimulating demands of the pharmaceutical sector of the modern world.

Indexed as

Aquatic OrganismsBiological ProductsPeptidesAnimalsDrug ApprovalEcosystemHumansSustainable DevelopmentUnited StatesUnited States Food and Drug AdministrationBiological ProductsPeptidesbioactivitiesbiomedicalmarine bioactive peptidesmarine biomenatural resourcespharmacologytherapeutic attributes

Identifiers

PMID35323507
PMCPMC8948685
OpenAlexW4221117125

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.